PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

As regards Pfizer, oncology sales ... of Pfizer’s diversified portfolio of drugs, particularly oncology, ... currently trade at 8.24 forward earnings, higher than 7.41 for Pfizer.

Estimates for Vertex Pharmaceuticals’ 2022 earnings have gone up from $14.52 to $14.56 per share, while those for 2023 have increased from $15.31 to $15.35 per share over the past 30 days.

Oncology’s Contribution To Pfizer’s EPS. We use adjusted net income margin of around 32%, similar to that of Pfizer overall, to arrive at $0.36 contribution to Pfizer’s total earnings.

Pfizer's earnings estimates beat expectations on Wednesday, due to the company's growing oncology business and slower-than-expected sales declines of its Covid-19 antiviral pill Paxlovid.

Pfizer's Vyndaqel heart disease drug - which earned ~$1.13bn revenues in Q1 2024, is also facing expiring patents - in 2025 in the US - as is Xeljanz, a former $2.5bn per annum autoimmune therapy ...

Additionally, Pfizer’s rapid advancement of several cancer drugs into phase 3 development opens the door to new blockbusters, including vepdegestrant (breast), sigvotatug vedotin (lung ...

Pfizer Chief Executive Albert Bourla is feeling more confident in his $43 billion acquisition of Seagen – thanks to the buzz around antibody-drug conjugate cancer drugs. “I feel way more ...

Pfizer’s PFE Biopharmaceuticals Group, which comprises six business units — Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine — is expected to have ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...